Moderna, Inc. Investing Cash Flow
Moderna, Inc. (MRNA) reported Investing Cash Flow of $253.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-31
- Moderna, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $329.00M, a 41.67% decline year-over-year.
- Moderna, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$76.00M, a 110.41% decline year-over-year.
- Moderna, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$48.00M.
- Moderna, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $700.00M, a 2.91% decline year-over-year.
- Moderna, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $1.95B, a 0.15% decline from fiscal 2024.
- Moderna, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $1.95B, a 53.66% decline from fiscal 2023.
- Moderna, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $4.21B.
- Moderna, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$5.18B.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $329.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $253.00M 10-Q · filed 2026-07-31 | $205.00M derived: sum of 3 quarters · filed 2026-07-31 | $905.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$76.00M 10-Q · filed 2026-05-01 | -$124.00M derived: sum of 2 quarters · filed 2026-05-01 | $576.00M derived: sum of 3 quarters · filed 2026-05-01 | $1.14B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $652.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.22B derived: sum of 3 quarters · filed 2026-07-31 | $1.95B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $700.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.26B derived: sum of 2 quarters · filed 2026-07-31 | $1.99B 10-Q · filed 2025-11-06 | $1.46B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $564.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $1.29B 10-Q · filed 2026-07-31 | $755.00M derived: sum of 3 quarters · filed 2026-07-31 | $1.48B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $730.00M 10-Q · filed 2026-05-01 | $191.00M derived: sum of 2 quarters · filed 2026-05-01 | $912.00M derived: sum of 3 quarters · filed 2026-05-01 | $2.56B derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$539.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $182.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.83B derived: sum of 3 quarters · filed 2026-02-20 | $1.95B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $721.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.37B derived: sum of 2 quarters · filed 2025-11-06 | $2.49B 10-Q · filed 2025-11-06 | $1.95B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $1.65B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $1.77B 10-Q · filed 2025-08-01 | $1.23B derived: sum of 3 quarters · filed 2026-02-20 | $2.02B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $118.00M 10-Q · filed 2025-05-01 | -$420.00M derived: sum of 2 quarters · filed 2026-02-20 | $369.00M derived: sum of 3 quarters · filed 2026-02-20 | $2.31B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | -$538.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $251.00M derived: sum of 2 quarters · filed 2026-02-20 | $2.19B derived: sum of 3 quarters · filed 2026-02-20 | $4.21B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $789.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.73B derived: sum of 2 quarters · filed 2024-11-07 | $4.74B 10-Q · filed 2024-11-07 | $3.70B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $1.94B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.96B 10-Q · filed 2024-08-01 | $2.91B derived: sum of 3 quarters · filed 2025-02-21 | $3.85B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $2.01B 10-Q · filed 2024-05-02 | $963.00M derived: sum of 2 quarters · filed 2025-02-21 | $1.91B derived: sum of 3 quarters · filed 2025-02-21 | $756.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | -$1.05B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$103.00M derived: sum of 2 quarters · filed 2025-02-21 | -$1.25B derived: sum of 3 quarters · filed 2025-02-21 | -$5.18B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $945.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$207.00M derived: sum of 2 quarters · filed 2023-11-03 | -$4.13B 10-Q · filed 2023-11-03 | -$5.27B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | -$1.15B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$5.07B 10-Q · filed 2023-08-03 | -$6.21B derived: sum of 3 quarters · filed 2024-02-23 | -$9.54B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | -$3.92B 10-Q · filed 2023-05-04 | -$5.06B derived: sum of 2 quarters · filed 2024-02-23 | -$8.39B derived: sum of 3 quarters · filed 2024-02-23 | -$12.26B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | -$1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$4.46B derived: sum of 2 quarters · filed 2024-02-23 | -$8.34B derived: sum of 3 quarters · filed 2024-02-23 | -$8.52B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | -$3.33B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$7.21B derived: sum of 2 quarters · filed 2022-11-03 | -$7.38B 10-Q · filed 2022-11-03 | -$7.58B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | -$3.88B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$4.06B 10-Q · filed 2022-08-03 | -$4.25B derived: sum of 3 quarters · filed 2023-02-24 | -$5.43B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | -$180.00M 10-Q · filed 2022-05-04 | -$370.00M derived: sum of 2 quarters · filed 2023-02-24 | -$1.55B derived: sum of 3 quarters · filed 2023-02-24 | -$1.54B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | -$190.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$1.37B derived: sum of 2 quarters · filed 2023-02-24 | -$1.36B derived: sum of 3 quarters · filed 2023-02-24 | -$1.67B 10-K · filed 2023-02-24 | -$1.67B 10-K · filed 2021-02-26 | |||
| 2020-09-30 | -$1.18B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$1.17B derived: sum of 2 quarters · filed 2021-11-04 | -$1.48B 10-Q · filed 2021-11-04 | -$1.48B 10-Q · filed 2020-10-30 | -$1.35B derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$303.00M 10-Q · filed 2021-08-05 | -$303.54M 10-Q · filed 2020-08-06 | -$172.71M derived: sum of 3 quarters · filed 2022-02-25 | -$59.34M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | -$316.00M 10-Q · filed 2021-05-06 | -$316.02M 10-Q · filed 2020-05-07 | -$185.71M derived: sum of 2 quarters · filed 2022-02-25 | -$72.34M derived: sum of 3 quarters · filed 2022-02-25 | -$319.24M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $130.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $243.66M derived: sum of 2 quarters · filed 2022-02-25 | -$3.24M derived: sum of 3 quarters · filed 2022-02-25 | -$15.00M 10-K · filed 2022-02-25 | -$14.95M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $113.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$133.53M derived: sum of 2 quarters · filed 2020-10-30 | -$145.29M 10-Q · filed 2020-10-30 | -$139.12M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | -$246.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$258.66M 10-Q · filed 2020-08-06 | -$252.49M derived: sum of 3 quarters · filed 2021-02-26 | -$136.41M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | -$11.76M 10-Q · filed 2020-05-07 | -$5.59M derived: sum of 2 quarters · filed 2021-02-26 | $110.50M derived: sum of 3 quarters · filed 2021-02-26 | $98.85M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $122.25M derived: sum of 2 quarters · filed 2021-02-26 | $110.61M derived: sum of 3 quarters · filed 2021-02-26 | -$373.09M 10-K · filed 2021-02-26 | -$372.47M 10-K · filed 2019-03-13 | |||
| 2018-09-30 | $116.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $104.44M derived: sum of 2 quarters · filed 2019-11-06 | -$379.27M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | -$11.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$495.35M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | -$483.70M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $417.36M 10-K · filed 2020-02-27 | $416.10M 10-K · filed 2019-03-13 | ||||||
| 2016-12-31 | -$648.61M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |